Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6,257 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma.
Santoni M, Conti A, Porta C, Procopio G, Sternberg CN, Basso U, De Giorgi U, Bracarda S, Rizzo M, Ortega C, Massari F, Iacovelli R, Derosa L, Masini C, Milella M, Di Lorenzo G, Atzori F, Pagano M, Buti S, De Vivo R, Mosca A, Rossi M, Paglino C, Verzoni E, Cerbone L, Muzzonigro G, Falconi M, Montironi R, Burattini L, Santini D, Cascinu S. Santoni M, et al. Among authors: rossi m. J Urol. 2015 Jan;193(1):41-7. doi: 10.1016/j.juro.2014.07.011. Epub 2014 Jul 18. J Urol. 2015. PMID: 25046616
Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis.
Bracarda S, Iacovelli R, Boni L, Rizzo M, Derosa L, Rossi M, Galli L, Procopio G, Sisani M, Longo F, Santoni M, Morelli F, Di Lorenzo G, Altavilla A, Porta C, Camerini A, Escudier B; Rainbow Group. Bracarda S, et al. Among authors: rossi m. Ann Oncol. 2015 Oct;26(10):2107-13. doi: 10.1093/annonc/mdv315. Epub 2015 Jul 27. Ann Oncol. 2015. PMID: 26216384 Free article.
Docetaxel rechallenge in metastatic castration-resistant prostate cancer: any place in the modern treatment scenario? An intention to treat evaluation.
Bracarda S, Caserta C, Galli L, Carlini P, Pastina I, Sisani M, Scali S, Hamzaj A, Derosa L, Felici A, Rossi M, Altavilla A, Chioni A, De Angelis V. Bracarda S, et al. Among authors: rossi m. Future Oncol. 2015 Nov;11(22):3083-90. doi: 10.2217/fon.15.217. Epub 2015 Oct 5. Future Oncol. 2015. PMID: 26437324
Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis.
Bracarda S, Iacovelli R, Boni L, Rizzo M, Derosa L, Rossi M, Galli L, Procopio G, Sisani M, Longo F, Santoni M, Morelli F, Di Lorenzo G, Altavilla A, Porta C, Camerini A, Escudier B; Rainbow Group. Bracarda S, et al. Among authors: rossi m. Ann Oncol. 2016 Feb;27(2):366. doi: 10.1093/annonc/mdv589. Epub 2015 Dec 18. Ann Oncol. 2016. PMID: 26685011 Free article. No abstract available.
Sunitinib therapy in metastatic papillary thyroid cancer.
Gori S, Foglietta J, Rossi M, Hamzaj A, Stocchi L, Galuppo C, Picece V, Puxeddu E, Furlani L. Gori S, et al. Among authors: rossi m. Tumori. 2013 Nov-Dec;99(6):285e-7e. doi: 10.1700/1390.15470. Tumori. 2013. PMID: 24503805
6,257 results